Before taking Tabrecta(Capmatinib)

Critical warnings and monitoring requirements for safe administration.

Precautions

TABRECTA treatment requires vigilant monitoring and management due to several boxed warnings. Patients should be closely monitored for new or worsening pulmonary symptoms indicative of ILD/pneumonitis, which warrants immediate and permanent discontinuation. Regular monitoring of liver function tests, amylase, and lipase is essential to manage risks of hepatotoxicity and pancreatic toxicity. Furthermore, patients should be advised about the potential for photosensitivity reactions and the critical need for effective contraception due to the risk of embryo-fetal toxicity. Concomitant use with strong or moderate CYP3A inducers should be avoided.